Pharmaceuticals

Rhinovirus Infections Drug Market Expansion Outlook: $1.89 Billion by 2029 Forecast

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Rhinovirus Infections Drug Market Between 2025 And 2029?

The rhinovirus infections drug market has experienced substantial growth in recent years. It is projected to expand from $1.26 billion in 2024 to $1.36 billion in 2025, at a compound annual growth rate (CAGR) of 7.7%. The market’s historical expansion is attributable to the increasing prevalence of the common cold, heightened awareness concerning respiratory infections, a rising demand for over-the-counter medications, increasing healthcare expenditure, and the growing adoption of combination therapies.

The rhinovirus infections drug market is projected to experience substantial expansion over the upcoming years. Its valuation is set to reach ” $1.89 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 8.7%. This anticipated growth during the forecast period stems from factors such as increasing investment in antiviral drugs, a rising need for targeted therapies, the growing incidence of respiratory disorders, improved healthcare accessibility in developing markets, and the expanding application of biologics and monoclonal antibodies. Key developments expected in this period encompass progress in antiviral research, breakthroughs in vaccine research, novel approaches in biologics and monoclonal antibodies, the creation of broad-spectrum antivirals, and innovations in nanotechnology for drug delivery.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23503&type=smp

Which Drivers Are Supporting Growth Of The Rhinovirus Infections Drug Market?

A rising prevalence of respiratory conditions is projected to boost the expansion of the rhinovirus infections drug market in the future. These conditions refer to medical ailments that impact the lungs and airways, leading to breathing difficulties, such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The increase in respiratory disorders is largely attributable to escalating air pollution and exposure to occupational hazards, contributing to conditions like asthma, COPD, and pneumonia, which are more widespread in affected populations. Rhinovirus infections drug assists respiratory disorders by targeting viral replication, diminishing inflammation, and alleviating symptoms to enhance respiratory function. For instance, in November 2023, according to the National Asthma Council, an Australia-based non-profit organization, in 2022, Australia reported 467 asthma-related deaths, including 299 females and 168 males, up from 355 deaths in 2021. Therefore, the growing occurrence of respiratory disorders propels growth in the rhinovirus infections drug market.

What Are The Different Segment Classifications Within The Rhinovirus Infections Drug Market?

The rhinovirus infections drug market covered in this report is segmented –

1) By Product: Antivirals, Immunomodulators, Vaccines, Nasal Sprays, Symptomatic Treatments

2) By Patient Age Group: Infants, Children, Adults, Elderly

3) By Route Of Administration: Oral, Intranasal, Injectable

4) By Indication: Common Cold, Asthma Exacerbation, Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Other Indications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

Subsegments:

1) By Antivirals: Pleconaril, Vapendavir, Rupintrivir, Other Antivirals

2) By Immunomodulators: Interferons, Toll-Like Receptor Agonists, Other Immunomodulators

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines

4) By Nasal Sprays: Antihistamine Nasal Sprays, Decongestant Nasal Sprays, Steroid Nasal Sprays, Saline Nasal Sprays

5) By Symptomatic Treatments: Analgesics, Antipyretics, Cough Suppressants, Expectorants, Antihistamines

How Are Trends Influencing The Rhinovirus Infections Drug Market?

Major companies operating in the rhinovirus infections drug market are dedicating efforts to creating advanced products, such as antiviral medications, to improve therapeutic outcomes, lessen the intensity of symptoms, and hasten patient recuperation. Antiviral drugs address viral infections by impeding viral replication inside the body. These medicines are capable of managing conditions like influenza, HIV, hepatitis, and rhinovirus. Certain antivirals hinder a virus’s entry into host cells, while others prevent its multiplication or assembly. For example, in March 2025, Altesa BioSciences Inc., a biotechnology firm based in the US, secured approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application concerning vapendavir, intended for treating rhinovirus infections in individuals with COPD. Vapendavir is an oral broad-spectrum antiviral medication that stops rhinovirus from penetrating human cells and replicating. It has demonstrated efficacy against 97% of rhinoviruses and other respiratory enteroviruses. Altesa BioSciences possesses the exclusive global rights for the development, manufacturing, and commercialization of vapendavir. The drug is designed to offer specialized treatment for susceptible groups, including those afflicted with COPD and asthma.

Which Key Market Players Are Investing In Expansion And Innovation Of Rhinovirus Infections Drug Market?

Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., BioFire Diagnostics LLC, hVIVO Services Limited, Romark Laboratories L.C., Cocrystal Pharma Inc., Altamira Therapeutics Ltd., Biota Pharmaceuticals Inc., Aditum Bio Management Company LLC, MetP Pharma AG, Via Nova Therapeutics Inc., Maxwell Biosciences Inc., Altesa BioSciences Inc., Apollo Therapeutics Group Limited, AIM ImmunoTech Inc., Bakar Labs, Ntvirin Pharma, bioRxiv, Pneumagen Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rhinovirus-infections-drug-global-market-report

Which Geographies Are Emerging As Strong Markets For The Rhinovirus Infections Drug Industry?

North America was the largest region in the rhinovirus infection drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Rhinovirus Infections Drug Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23503&type=smp

Browse Through More Reports Similar to the Global Rhinovirus Infections Drug Market 2025, By The Business Research Company

Antivirus Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antivirus-software-global-market-report

Coronavirus Covid 19 Current Therapy Market 2025

https://www.thebusinessresearchcompany.com/report/coronavirus-covid-19-current-therapy-market

Virus Filtration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/virus-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795